Duchenne refers to Duchenne muscular dystrophy (DMD), a genetic condition that causes progressive muscle weakness and is named after Guillaume Duchenne de Boulogne, the French neurologist who first described it in the late 19th century. It affects roughly 1 in 3,500 to 5,000 live male births worldwide, making it the most common form of muscular dystrophy.
The Name Behind the Condition
Guillaume Duchenne de Boulogne was a French neurologist who pioneered the study of muscle diseases. His detailed clinical descriptions of boys losing the ability to walk, then gradually losing function in nearly every muscle group, established Duchenne muscular dystrophy as a distinct condition. The name stuck as a medical convention, much like Parkinson’s disease or Alzheimer’s.
Today, when someone says “Duchenne” without further context, they’re almost always referring to Duchenne muscular dystrophy. You may also encounter “Duchenne smile” in psychology (a genuine smile that engages the muscles around the eyes), which Duchenne de Boulogne also studied. But the muscular dystrophy is by far the most common use of the term.
What Causes Duchenne Muscular Dystrophy
Duchenne is caused by mutations in the dystrophin gene, which sits on the X chromosome. This gene is the largest known human gene, containing 79 exons and spanning roughly 0.1% of the entire human genome. Its job is to produce a protein called dystrophin, which acts like a shock absorber for muscle cells. Dystrophin stabilizes the outer membrane of muscle fibers during contraction, preventing damage every time a muscle flexes.
When the dystrophin gene is mutated, muscle cells produce little or no functional dystrophin. Without that protective scaffolding, muscle fibers tear and break down with normal use. The body replaces damaged muscle with scar tissue and fat, which can’t contract. Over time, muscles throughout the body progressively weaken. The most common type of mutation is a deletion of one or more sections of the gene, which accounts for 60 to 70% of all Duchenne cases. Point mutations, smaller errors in the genetic code, cause about 26% of cases.
Why It Almost Exclusively Affects Boys
Because the dystrophin gene is on the X chromosome, Duchenne follows an X-linked recessive inheritance pattern. Boys have one X and one Y chromosome, so a single mutated copy of the gene is enough to cause the disease. Girls have two X chromosomes, meaning a working copy on the second X chromosome typically compensates for a mutated one. Girls who carry one mutated copy are called carriers and usually don’t develop significant symptoms, though some carriers experience mild muscle weakness or heart problems.
A mother who is a carrier has a 50% chance of passing the mutated gene to each child. Each son who inherits it will have Duchenne; each daughter who inherits it will be a carrier. However, about one-third of Duchenne cases arise from new, spontaneous mutations, meaning the child’s mother is not a carrier and there’s no family history of the disease.
How Duchenne Is Recognized
Duchenne typically becomes noticeable between ages 2 and 5. Early signs include difficulty running, climbing stairs, or getting up from the floor. One hallmark is Gower’s sign: a child who, when trying to stand up from a sitting position, places their hands on their thighs and “walks” them upward to push themselves upright. This compensatory maneuver reveals weakness in the hips and upper legs. In early stages, a child might just press lightly against their thighs. As the disease progresses, they need to push off the floor with both hands.
Another early clue is unusually large calf muscles. This looks like strength, but the calves are actually enlarged because muscle tissue is being replaced by fat and scar tissue, a process called pseudohypertrophy. Children with Duchenne also tend to walk on their toes and have a waddling gait.
When a doctor suspects Duchenne, a blood test measuring a muscle enzyme called creatine kinase (CK) is usually the first step. A person without Duchenne typically has CK levels below 200 units per liter. In Duchenne, levels run 10 to 100 times that range, reflecting the constant breakdown of muscle fibers. Genetic testing then confirms the specific mutation.
How the Disease Progresses
Duchenne follows a fairly predictable timeline, though the pace varies from person to person. In early childhood, boys can walk and play but fall behind peers physically. Muscle weakness starts in the hips, thighs, and shoulders and gradually spreads outward. Most boys with Duchenne begin using a wheelchair between ages 10 and 12 as leg muscles can no longer support walking.
The disease doesn’t stop at skeletal muscles. The heart, which is also a muscle, becomes affected over time. Heart monitoring with imaging and electrocardiograms typically begins around age 6. Breathing muscles also weaken, eventually requiring assisted ventilation, first at night and later full-time. These cardiac and respiratory complications are the primary drivers of life expectancy in Duchenne.
A large meta-analysis published in Neurology found that the overall median life expectancy for people with Duchenne is 22 years. But this number has improved dramatically with modern care. For those born after 1990, who benefited from steroid treatment and better respiratory and cardiac support, median life expectancy rose to 28.1 years. For comparison, patients born before 1970 had a median survival of just 18.1 years. The trend continues to improve as new therapies emerge.
Treatment and Management
There is no cure for Duchenne, but treatment has shifted significantly over the past few decades. Corticosteroids remain the backbone of management, slowing muscle breakdown and helping boys walk independently for longer. Physical therapy and stretching help maintain flexibility and delay joint contractures, where muscles and tendons shorten permanently.
On the cardiac side, medications that reduce strain on the heart are started early, often around age 6 to 10, to delay the onset of heart failure. Respiratory support, including devices that assist with coughing and nighttime breathing machines, extends life substantially once breathing muscles weaken.
Gene therapy represents a newer frontier. In 2023, the FDA approved a gene therapy called Elevidys for ambulatory patients aged 4 and older with a confirmed dystrophin gene mutation. Rather than fixing the mutated gene itself, this therapy delivers a shortened but functional version of the dystrophin gene into muscle cells using a modified virus as a delivery vehicle. The goal is to give muscle cells enough dystrophin to slow or reduce damage. It’s a single intravenous infusion, though long-term outcomes are still being tracked.
Duchenne vs. Becker Muscular Dystrophy
You’ll sometimes see Becker muscular dystrophy mentioned alongside Duchenne. Both are caused by mutations in the same dystrophin gene, but they differ in severity. In Duchenne, the mutation essentially stops dystrophin production. In Becker, the mutation allows the body to produce a shorter, partially functional version of the protein. As a result, Becker progresses more slowly, with symptoms appearing later in childhood or even in adolescence, and people with Becker generally live longer. The same types of mutations cause both conditions: deletions account for 80 to 85% of Becker cases, compared to 60 to 70% of Duchenne cases.